Qube Research & Technologies (QRT)
EWTX icon

Qube Research & Technologies (QRT)’s Edgewise Therapeutics EWTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.9M Buy
1,252,507
+426,597
+52% +$14.7M 0.05% 492
2026
Q1 		$26M Buy
825,910
+529,702
+179% +$15.3M 0.03% 728
2025
Q4 		$7.35M Sell
296,208
-259,505
-47% -$5.21M 0.01% 1536
2025
Q3 		$9.01M Buy
555,713
+55,796
+11% +$791K 0.01% 1396
2025
Q2 		$6.55M Buy
499,917
+102,344
+26% +$1.48M 0.01% 1550
2025
Q1 		$8.75M Buy
397,573
+28,131
+8% +$738K 0.01% 1218
2024
Q4 		$9.86M Buy
369,442
+237,550
+180% +$7.56M 0.01% 1096
2024
Q3 		$3.52M Buy
131,892
+103,047
+357% +$2.05M 0.01% 1549
2024
Q2 		$519K Buy
28,845
+19,843
+220% +$346K ﹤0.01% 2135
2024
Q1 		$164K Buy
9,002
+6,976
+344% +$111K ﹤0.01% 3117
2023
Q4 		$22.2K Buy
+2,026
New +$14.2K ﹤0.01% 3470
2022
Q1 		– Sell
-18,078
Closed -$276K – 2607
2021
Q4 		$276K Buy
+18,078
New +$325K ﹤0.01% 1839

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT)'s EWTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Edgewise Therapeutics (EWTX) stake by 52% in Q2 2026, buying an estimated $14.7M and bringing the position to 1,252,507 shares worth $50.9M. The position accounts for 0.05% of the portfolio, ranked #492.

Qube Research & Technologies (QRT) first reported a position in EWTX in Q4 2021 and has held it in 12 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 1,252,507 shares of Edgewise Therapeutics worth $50.9M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 426,597 Edgewise Therapeutics shares in Q2 2026, an estimated $14.7M.
  • Edgewise Therapeutics made up 0.05% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #492 holding.
  • Qube Research & Technologies (QRT) first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.